Perspectives

September 2023 

Carelon Research curates the Healthcare Integrated Research Database, or HIRD, as one of the largest, most comprehensive healthcare databases in the US. Experts at Carelon Research apply decades of experience developing and analyzing the HIRD to effectively generate real-world evidence in collaboration with clients.  

This technical white paper is tailored for healthcare researchers within life sciences, government, and academia evaluating the potential of the HIRD as a real-world data resource for their research.


Download the white paper




Ready to learn more? Let's connect. 




This form collects your name and email. By submitting this form you are giving permission for us to contact you with information about our services.

For more information on how we protect and manage your submitted data, please read our privacy policy.

This form collects your name and email. By submitting this form you are giving permission for us to contact you with information about our services.

For more information on how we protect and manage your submitted data, please read our privacy policy.

Ready to learn more? Let's connect.

This form collects your name and email. By submitting this form you are giving permission for us to contact you with information about our services.

For more information on how we protect and manage your submitted data, please read our privacy policy.

This form collects your name and email. By submitting this form you are giving permission for us to contact you with information about our services.

For more information on how we protect and manage your submitted data, please read our privacy policy.

Highlighted Studies

A real-world study of immunoglobulin (IG) reveals multiple cost-saving opportunities 

Hub Domain(s): Immunology, oncology, costs of care, IngenioRx, policy guidance
Summary: 

  • Background: Immunoglobulins (IG) are costly blood-derived products accounting for more than $500m in annual spending in the Anthem membership
  • Methods: HealthCore examined IG utilization using claims data to evaluate appropriateness of use, the extent of site-of-care optimization and non-preferred IG use.
  • Results: The findings revealed significant off-label use of IGs (30%), including 22% for indications that were neither approved by FDA nor covered by Anthem, but were accepted by other health plans; and 8% for indications that were neither approved by FDA nor covered by any health plan
    • Additionally, 25% of the IG use was observed in the most expensive site of administration of hospital outpatient (HOPD) and non-preferred IG use accounted for 71% of the total IG use
  • Key Takeaways: Examining the IG uses from various dimensions presents several opportunities to IngenioRx and Anthem:
    • Reducing off-label IG use represented an estimated $27.8m annual savings opportunity
    • Shifting IG utilization from HOPD to a less expensive site of care could drive a further estimated $6.3m in annual savings
    • The study also identified opportunities to increase the share of preferred IG products used by our patients.


Major depressive disorder (MDD) patients highly impacted by COVID-19 face daunting challenges

Hub Domain(s): COVID, member experience
Summary: 

  • Background: Disruption to daily life and lockdown measures that were imposed in an attempt to contain the spread of COVID-19 presented new hurdles for at-risk populations, such as patients with major depressive disorder (MDD)
  • Methods: Conducted a 2020 internet survey to understand reasons for antidepressant continuation, switching and discontinuation in patients with MDD; COVID-19 pandemic questions were developed and added to survey.
    • COVID-19 Pandemic Impact (CPI) score was calculated and, based on their CPI scores, patients were categorized as experiencing low (LPI), medium (MPI) or high pandemic impact (HPI).
  • Results: Compared with LPI and MPI patients, HPI patients reported:
    • Significantly more problems accessing healthcare; few reported not having health insurance benefits due to loss of/reduced health insurance coverage (Figure 1).
    • More challenges obtaining depression prescription medications in terms of:
      • Filling new/current prescription(s)
      • Receiving samples from healthcare providers
      • Paying for prescription(s) due to loss of/reduced health insurance coverage and/or pharmacy benefits
    • Since start of COVID-19 pandemic engaged in significantly more:
      • Alcohol, drug, and tobacco use
      • Unhealthy mindless eating
      • Sedentary behavior
  • Key Takeaways: Our findings are consistent with literature showing that traumatic events, e.g. pandemics, can negatively impact health behaviors.
    • More research is needed to explore the COVID-19 impact in other patient populations.
    • Education opportunities exist for health plans to increase awareness among providers and patients of possible short and long-term COVID-19 effects on health behaviors.

Figure 1: Impact of COVID-19 pandemic on accessing healthcare/mental healthcare

  • Publications: Poster presented at the Virtual American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, June 1-4, 2021

Patient-centered research at Carelon Research

Learn how this team is using innovative approaches to gather the patient perspective.

[Perspectives] Innovative approaches to gathering the patient perspective

The PCR team goes beyond numbers to inform meaningful research solutions with rich, in-depth insights.

[Perspectives] Survey research: Elements of a “good” survey

Survey research is a critical component of patient-centered research.

Consectetur adipiscing elit...

"Et harum quidem rerum facilis est et expedita distinctio!"

Stanley T.

"Nam libero tempore, cum soluta nobis est eligendi."

Danielle W.

"Temporibus autem quibusdam et aut officiis debitis!"

Teams at Carelon Research